论文部分内容阅读
Bepridil 为一新的钙通道阻滞剂,血浆清除半衰期>50小时。本文在中度慢性稳定型心绞痛患者中估价其短程抗心绞痛的疗效及三种不同剂量的安全性,并对每日一次及二次给药法作了评价。方法:77例慢性稳定型劳累型心绞痛且6个月内无心肌梗塞者,其中男71例,女6例,平均年龄58岁。对先前曾用抗心绞痛治疗的患者先经约三周的药物清除阶段,随后给予安慰剂每日二次共二周。测定每日心绞痛频数、硝酸甘油用量、卧位和立
Bepridil is a new calcium channel blocker with a plasma clearance half-life> 50 hours. This article evaluated the efficacy of short-course anti-anginal pectoris and the safety of three different doses in patients with moderate-to-severe chronic stable angina and evaluated the once- and twice- daily dosing regimens. Methods: Totally 77 patients with stable chronic angina and 6 patients without myocardial infarction within 6 months, including 71 males and 6 females, with an average age of 58 years. Patients who had previously been treated with anti-angina were followed by a drug clearance phase of about three weeks followed by a placebo twice daily for two weeks. Determination of daily angina frequency, nitroglycerin dosage, supine position and legislation